Trial
Neurology

Caregiver Characteristics That May Predict When Patients With Alzheimer Disease Are Placed in Long Term Care Facilities

Active recruiting
This research will be conducted by the SIU Memory and Aging Network (MAN), which comprises 38 sites that evaluate and treat patients with dementia throughout non-metropolitan Illinois.  AD patients and their caregivers who are living in private homes will be recruited.  Primary outcome measures will be the ratings of the caregiver’s physical status (grip strength, walking speed, and score on the Timed Up-and-Go Test11 and the rating of the caregiver’s chronic medical illness burden using the Cumulative Illness Rating Scale (Geriatric).12,13  The patient and caregiver dyad is required.
Contact: Stephanie Kohlrus 217-545-3013
Trial
Neurology

Roche: A Phase IIB, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of intravenous prasinezumab in participants with early Parkinson's disease

Active not recruiting

This study will evaluate the efficacy, safety, and pharmacokinetics of prasinezumab compared with placebo in patients with early Parkinson's disease (PD).

Contact: Rylee Manka 217-545-1394
Trial
Psychiatry

RECOVER: A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy System as Adjunctive Therapy Versus a No-Stimulation Control in Subjects with Treatment-Resistant Depression

Active recruiting

The RECOVER study is a nationwide clinical trial that has been approved by Medicare to provide additional evidence for the benefits of Vagus Nerve Stimulation (VNS) Therapy.  Vagus Nerve Stimulation Therapy is an FDA-approved device for treating patients with TRD (Treatment Resistant Depression). It is implanted in the left chest area during a short outpatient procedure. The device delivers mild, intermittently pulsed signals to the vagus nerve in the neck that activate various parts of the brain.

Contact: Oladele (Dickson) Owasoyo 217-545-7231
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
News

SIU Medicine enrolling patients for clinical study to treat depression

SPRINGFIELD, ILLINOIS, October 18, 2021 – Clinical depression affects more than 17 million people in the United States. Among those afflicted, 1 out of 3 has what is called treatment-resistant depression (TRD). Despite medical help, they have been unable to find adequate relief from their symptoms. A new clinical trial at SIU School of Medicine is testing a treatment that could help those with recurring depression. “Depression is a common mental disorder that can become disabling if not treated,” said Jeffrey Bennett, MD, professor of psychiatry at SIU School of Medicine and the principal
Trial
Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

Contact: Sara Boarman 217-545-6829
Trial
Neurology

Lilly: Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease

Active not recruiting

I5T-MC-AACI:  The purpose of this study is to assess the effect of donanemab versus placebo on clinical regression in participants with early symptomatic Alzheimer's disease with presence of low-medium tau pathology.

Contact: Sara Boarman 217-545-6829
News

Report, Webinar Focuses on Impact of COVID-19 and the Rural Health Workforce

SPRINGFIELD, IL – A new report dissects the impact of COVID-19 on the rural health workforce and identifies methods the state can utilize current health workers more efficiently while committing to long-term rural health workforce recruitment strategies. “Pre-pandemic, rural regions suffered from significant healthcare provider shortages, which often required rural residents to travel long distances or wait longer for appointments,” said Dr. Sameer Vohra, Chair, SIU Medicine Department of Population Science and Policy. “Despite rural health workers’ heroic efforts during the pandemic, job
General Results

Denim and Diamonds Annual Event

Subscribe to Research